DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study

Kana Miyazaki,1 Naoko Asano,2 Tomomi Yamada,2 Kohta Miyawaki,4 Rika Sakai,1 Tadahiko Igarashi,4 Momoko Nishikori,1 Kinya Ohata,8 Kazutaka Sunami,9 Isao Yoshida,10 Go Yamamoto,12 Naoki Takahashi,12 Masataka Okamoto,13 Hiroki Yano,14 Yuki Nishimura,13 Satoshi Tamaru,13 Masakatsu Nishikawa,12 Koji Izutsu,11,12 Tomohiro Kinoshita,17 Junji Suzumiya,19 Koichi Ohshima,3 Koji Kato,4 Naoyuki Katayama1 and Motoko Yamaguchi2

1Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie; 2Department of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka; 3Department of Medical Innovation, Osaka University Hospital, Suita; 4Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka; 5Department of Medical Oncology, Kanagawa Cancer Center, Yokohama; 6Hematology/Oncology Division, Gunma Cancer Center, Ohta; 7Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto; 8Department of Hematology, Kanazawa University, Kanazawa; 9Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama; 10Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama; 11Department of Hematology, Toranomon Hospital, Tokyo; 12Department of Hematology and Oncology, International Medical Center, Saitama Medical University, Hidaka; 13Department of Hematology, Fujita Health University School of Medicine, Toyoake; 14Department of Hematology, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi; 15Clinical Research Support Center, Mie University Hospital, Tsu; 16Department of Hematology, National Cancer Center Hospital, Tokyo; 17Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya; 18Department of Oncology and Hematology, Shimane University Hospital, Izumo and 19Department of Pathology, Kurume University School of Medicine, Kurume, Japan

ABSTRACT

CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) is characterized by poor prognosis and a high frequency of central nervous system relapse after standard immunochemotherapy. We conducted a phase II study to investigate the efficacy and safety of dose-adjusted (DA)-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) combined with high-dose methotrexate (HD-MTX) in newly diagnosed patients with CD5+ DLBCL. Previously untreated patients with stage II to IV CD5+ DLBCL according to the 2008 World Health Organization classification were eligible. Four cycles of DA-EPOCH-R followed by two cycles of HD-MTX and four additional cycles of DA-EPOCH-R (DA-EPOCH-R/HD-MTX) were planned as the protocol treatment. The primary end point was 2-year progression-free survival (PFS). Between September 25, 2012, and November 11, 2015, we enrolled 47 evaluable patients. Forty-five (96%) patients completed the protocol treatment. There were no deviations or violations in the DA-EPOCH-R dose levels. The complete response rate was 91%, and the overall response rate was 94%. At a median follow up of 3.1 years (range, 2.0-4.9 years), the 2-year PFS was 79% [95% confidence interval (CI): 64-88]. The 2-year overall survival was 89% (95% CI: 76-95). Toxicity included grade 4 neutropenia in 46 (98%) patients, grade 4 thrombocytopenia in 12 (26%) patients, and febrile neutropenia in 31 (66%) patients. No treatment-related death was noted during the study. DA-EPOCH-R/HD-MTX might be a first-line therapy option for stage II-IV CD5+ DLBCL and warrants further investigation. (Trial registered at: UMIN-CTR: UMIN000008507.)
Introduction

Diffuse large B-cell lymphoma (DLBCL) includes a heterogeneous group of lymphomas with various clinicopathological and genetic features. The current standard first-line therapy of DLBCL is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Gene expression profiling (GEP) has identified activated B-cell-like (ABC), germinal center B-cell-like (GCB), and unclassified DLBCL. ABC DLBCL exhibits worse prognosis than GCB DLBCL after R-CHOP.

CD5-positive (CD5+) DLBCL is an immunohistochemical subgroup of DLBCL, not otherwise specified (NOS) in the 2008 World Health Organization (WHO) classification and accounts for 5-10% of DLBCL. It is associated with various clinical characteristics, such as elderly onset, advanced stage at diagnosis, elevated lactate dehydrogenase (LDH) level, and frequent involvement of extranodal sites. Ninety percent of CD5+ DLBCL cases are positive for BCL2, which has been reported as a risk factor for short survival in DLBCL. The patients with CD5+ DLBCL show significantly worse survival than those with CD5-negative (CD5-) DLBCL after R-CHOP and is also characterized by a high incidence of central nervous system (CNS) relapse (8-13%), mainly brain parenchymal relapse. CNS relapse strongly affects the prognosis of CD5+ DLBCL. Up to 80% of CD5+ DLBCL are classified as ABC DLBCL by GEP, and CD5 expression is significantly associated with the poor prognosis of patients with ABC DLBCL.

Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) is an infusional regimen that incorporates a dynamic dose adjustment and has shown excellent efficacy in BCL2- DLBCL. High-dose methotrexate (HD-MTX) is commonly used in the treatment of primary DLBCL of the CNS. To explore a more effective first-line chemotherapy for CD5+ DLBCL, we have been investigating DA-EPOCH-R combined with high-dose methotrexate (HD-MTX) therapy (DA-EPOCH-R/HD-MTX) since 2009. In 2009, when we were planning this study, eight cycles of R-CHOP was used as the standard treatment for the patients with advanced DLBCL. In previous phase II trials using DA-EPOCH-R, patients received two cycles beyond complete response (CR) or stable changes after six cycles of DA-EPOCH-R. Considering the aggressiveness of CD5+ DLBCL, we selected eight cycles of DA-EPOCH-R based on the maximum number of cycles in original studies of DA-EPOCH-R. Because most CNS relapse events in patients with CD5+ DLBCL during R-CHOP have been documented within 6 months after diagnosis, we added two cycles of HD-MTX between the fourth and fifth cycles of DA-EPOCH-R. The protocol treatment comprised four cycles of DA-EPOCH-R followed by two cycles of HD-MTX and four additional cycles of DA-EPOCH-R.
intervals (CI) were estimated using Greenwood’s formula. All analyses were performed using SAS v9.4 (Cary, NC, USA) statistical package.

Results

Patients’ characteristics
A total of 47 patients from 24 participating institutions were enrolled in the study between July 2012 and November 2015 (Figure 1). The central pathology review confirmed the diagnosis of all patients as CD5+ DLBCL based on the 2008 WHO criteria. The review also revealed that two patients had high-grade B-cell lymphoma, NOS based on the 2017 WHO classification. The baseline clinical features and disease characteristics are listed in Table 1. Thirty-six percent of the patients were over 65 years of age. Skin/subcutaneous tissue was the most frequent site of extranodal involvement (15%). One patient had primary testicular DLBCL.

For one case, the quality of the RNA extracted from the FFPE tissue sample was inadequate, but the remaining 46 cases were analyzed using GEP. Thirty-nine (85%) of 46 cases were classified as ABC DLBCL, four (9%) were classified as GCB DLBCL, and three (7%) were unclassified. The morphological and immunophenotypical features are summarized in Table 2. Based on Hans’ criteria, 72% of the 46 patients examined were classified as non-GCB DLBCL.

Treatment and response
Forty-five (96%) patients completed the protocol treatment. In the remaining two patients, treatment was discontinued because of tumor lysis syndrome (TLS) with hyperkalemia after the first administration of rituximab and grade 3 stomatitis during the sixth cycle of DA-EPOCH-R. The dose-adjustment map of DA-EPOCH-R is shown in Online Supplementary Figure S2. The range of the dose level of DA-EPOCH-R was 1-4; median dose level of DA-EPOCH-R was two. The maximum dose level of DA-EPOCH-R was 1 in 26.1%, 2 in 32.6%, 3 in 26.1%, 4 in 15.2%, and >4 in 0%. There were no deviations or violations in determining the dose levels of DA-EPOCH-R. All patients were administered with DA-EPOCH-R/HD-MTX entirely in the hospital. Of the 47 patients evaluable for response, 43 patients achieved a CR (91%; 95%CI: 80-98%), one patient achieved a partial response, and two patients experienced progressive disease. The ORR was 94% (95%CI: 82-99%).

Survival
With a median follow up of 3.1 years (range, 2.0-4.9), the 2-year PFS was 79% (90%CI: 67-87%; 95%CI: 64-88%) (Figure 2A). This finding compared favorably with that of the historical control (51%). The 2-year OS was 89% (90%CI: 79-95%; 95%CI: 76-95%) (Figure 2B). One patient with CR died in a traffic accident 0.8 years after enrollment.

In a preplanned exploratory subgroup analysis, there was no significant difference in PFS (Online Supplementary Figure S3A) or OS (Online Supplementary Figure S3B) according to COO categories. The 2-year PFS and OS for CD5+ ABC DLBCL (n=39) were 77% and 87%, respectively. There was no significant difference in PFS according to gender and each risk factor for IPI (data not shown).

Central nervous system relapse
The 2-year CNS relapse rate was 9% (n=4; 90%CI: 4-19%, 95%CI: 3-21%) (Figure 3A). During the follow-up period, no patient experienced CNS relapse more than 2 years from enrollment. There was no significant difference in PFS among the CNS-IPI categories (P=0.58) (Figure 3B). Ten patients in the CNS IPI high-risk group were classified as ABC (n=8), GCB (n=1), and unclassified DLBCL (n=1).

The clinical characteristics of four patients who experienced CNS relapse are summarized in Online Supplementary Table S2. Among them, one patient had primary testicular DLBCL. Two patients were diagnosed as having high-grade B-cell lymphoma, NOS with MYC rearrangement based on the 2017 WHO criteria. Neither of these patients had the BCL2 translocation, and both were positive for CD10 and BCL2 by immunohistochemistry. For the remaining one patient, the protocol treat-
ment was discontinued after the first drug administration due to grade 4 TLS. CNS relapses occurred in two patients (one patient had leptomeningeal disease with tumor of ethmoid sinus, and the other patient had brain parenchymal disease alone) before HD-MTX of the protocol treatment.

Toxicity
Toxicity was assessed in all 445 cycles of DA-EPOCH-R/HD-MTX with 357 cycles of DA-EPOCH-R in all 47 patients. Table 3 lists adverse events in all 445 cycles of DA-EPOCH-R/HD-MTX, and Online Supplementary Table S3 lists adverse events in 357 cycles of DA-EPOCH-R. There were no treatment-related deaths. The most common grade 3 non-hematologic toxicity was elevated ALT (28%). Four patients experienced grade 3 infection, including catheter-related infection, cellulitis, endocarditis, and urinary tract infection. Grade 3 peripheral motor neuropathy and peripheral sensory neuropathy occurred in 4% of patients, separately. There was no grade 3 cardiac toxicity. Grade 4 neutropenia and thrombocytopenia were present in 98% and 26% of patients, respectively.

The targeted ANC (<0.5x10^9/L) occurred in 77% of cycles. Thrombocytopenia of <25x10^9/L occurred in 8% of cycles. Febrile neutropenia (FN) occurred in 66% of patients and 25% per cycle of DA-EPOCH-R and had available follow-up data, the 2-year PFS was 51%. Recently, the results of several retrospective studies of CD5+ DLBCL in the rituximab-era (R-era) were reported. In both cohorts of 102 patients with all stage CD5+ DLBCL who received rituximab-containing chemotherapy (R-chemo) and had available follow-up data, the 2-year PFS was 51%. Recently, the results of several retrospective studies of CD5+ DLBCL in the rituximab-era (R-era) were reported. In both cohorts of 102 patients with all stage CD5+ DLBCL who received R-chemo at nine institutes in the United States and 81 patients with all stage CD5+ DLBCL who received R-CHOP in other Western countries, the 2-year OS was less than 50%. Therefore, we consider that our threshold setting was reasonable and that the 2-year DFS (79%) by the protocol treatment in our present study was superior to the historical control.

Few reports have described the use of DA-EPOCH-R for CD5+ DLBCL. For all DLBCL subtypes, there was no sig-

Table 1. Baseline clinical features and disease characteristics.

| Characteristic                               | All patients (n=47) |
|---------------------------------------------|---------------------|
| Age, years                                  | 62                  |
| Median                                      | 37-74               |
| >60 years                                   | 28 (60%)            |
| Sex                                         |                     |
| Male                                        | 18 (38%)            |
| Female                                      | 29 (62%)            |
| Stage                                       |                     |
| II                                          | 20 (43%)            |
| III-IV                                      | 27 (57%)            |
| ECOG PS                                     |                     |
| 0 or 1                                      | 45 (96%)            |
| >1                                          | 2 (4%)              |
| Serum LDH level                             |                     |
| Normal                                      | 16 (34%)            |
| Elevated                                    | 31 (66%)            |
| Extraneodial sites                          |                     |
| 0 or 1                                      | 31 (66%)            |
| >1                                          | 16 (34%)            |
| IPI risk category                           |                     |
| Low/Low-intermediate                        | 25 (53%)            |
| High-intermediate/High                      | 22 (47%)            |
| CNS-IPI risk category                       |                     |
| Low                                         | 14 (30%)            |
| Intermediate                                | 23 (49%)            |
| High                                        | 10 (21%)            |
| Cell-of-origin*                             |                     |
| ABC                                         | 39 (85%)            |
| GCB                                         | 4 (9%)              |
| Unclassified                                | 3 (7%)              |

Table 2. Morphological and immunophenotypical features.

| Characteristic                               | All patients (n=47) |
|---------------------------------------------|---------------------|
| Morphology                                  |                     |
| Common variant                              | 31 (60%)            |
| Giant cell rich variant                     | 3 (6%)              |
| Polymorphic variant                         | 12 (26%)            |
| Immunoblastic variant                       | 1 (2%)              |
| Immunohistochemistry                        |                     |
| CD5*                                        | 47 (100%)           |
| CD20                                        | 47 (100%)           |
| CyclinD1                                    | 0 (0%)              |
| CD10*                                       | 13 (28%)            |
| BCL6*                                       | 39 (85%)            |
| MYC*                                        | 44 (96%)            |
| MUM1*                                       | 4 (9%)              |
| MYC positive/BCL2 positive†                 | 26 (57%)            |
| COO subtype by Hans’ criteria               |                     |
| GCB*                                        | 13 (28%)            |
| Non-GCB†                                     | 33 (72%)            |
| EBER in situ†                                | 0 (0%)              |

COO: cell-of-origin; EBER: Epstein-Barr virus-encoded RNA-1; GCB: germinal center-B-cell-like. *Assessed by flow cytometry in 4 patients. †Examined in 46 patients.

Discussion
To the best of our knowledge, this is the first clinical trial for CD5+ DLBCL. At the beginning of this trial in 2015, we calculated the threshold 2-year PFS using our previous retrospective study including 337 patients with CD5+ DLBCL. In 149 patients with newly diagnosed stage II-IV CD5+ DLBCL who received rituximab-containing chemotherapy (R-chemo) and had available follow-up data, the 2-year PFS was 51%. Recently, the results of several retrospective studies of CD5+ DLBCL in the rituximab-era (R-era) were reported. In both cohorts of 102 patients with all stage CD5+ DLBCL who received R-chemo at nine institutes in the United States and 81 patients with all stage CD5+ DLBCL who received R-CHOP in other Western countries, the 2-year OS was less than 50%. Therefore, we consider that our threshold setting was reasonable and that the 2-year DFS (79%) by the protocol treatment in our present study was superior to the historical control.

Few reports have described the use of DA-EPOCH-R for CD5+ DLBCL. For all DLBCL subtypes, there was no sig-
significant difference in survival between patients who received R-CHOP and patients who received DA-EPOCH-R in a large randomized controlled trial. In that trial, the prognosis stratified by CD5 was not shown. In the largest study including 130 DLBCL patients who were examined for CD5 expression and received DA-EPOCH-R, 16 (12.3%) patients had CD5+ DLBCL. At a median follow up of 28.5 months, 37.5% of patients in the CD5+ DLBCL group had died, which showed a significantly worse survival than those in the CD5- DLBCL. The 2-year OS was 89% (90%CI: 79-95%; 95%CI: 76-95%) for DA-EPOCH-R/HD-MTX in our present trial.

In a large retrospective study including 102 patients with CD5+ DLBCL, 6 of 7 patients with untreated CD5+ DLBCL who received DA-EPOCH-R achieved a CR and were disease-free with a median follow up of 30 months. In another study, CD5 expression in DLBCL was identified as a risk factor for short OS in a cohort of patients who received R-EPOCH, which indicated that R-EPOCH alone may be insufficient to cure this disease. In the present study of stage II-IV CD5+ DLBCL, HD-MTX therapy was added between the fourth and fifth cycles of DA-EPOCH-R. In our trial, the completion rate of the protocol treatment was high. Moreover, there were no deviations or violations in the dose-adjustment of DA-EPOCH-R. All patients received DA-EPOCH-R/HD-MTX only in the hospital. These features may have contributed to the excellent efficacy of DA-EPOCH-R/HD-MTX in our trial. However, a considerable number of female patients (62%), patients with PS <2 (96%), and those with...
low/low-intermediate IPI risk (53%) were enrolled in the present study. In the subgroup analysis of PFS, there was no significant difference between those with and those without risk factors for gender, PS, and IPI group, although the sample size was small. Considering these results, further studies are needed to establish DA-EPOCH-R/HD-MTX as a standard therapy for newly diagnosed stage II-IV CD5+ DLBCL. Nevertheless, we consider that this regimen might be regarded as a treatment option, because CD5 expression can be easily examined in clinical practice.

The incidence of CNS relapse for all patients with DLBCL treated with R-CHOP has been reported to be 1.9-6.4%, whereas the incidence of CNS relapse for CD5+ DLBCL in the R-era were reported as 13% in our retrospective study, 8% in a study in Western countries, and 33% in ten patients treated with DA-EPOCH-R in a retrospective study. Although our present trial does not have a sufficient statistical power to assess the reduction in CNS relapse, the incidence of CNS relapse in the present study (9%; 95% CI: 3-21%) seems to be lower than that for DA-EPOCH-R alone. To further reduce the incidence of CNS relapse, development of systemic chemotherapy in combination with one or more newer agents that cross the blood-brain barrier, including ibritumomab tiuxetan and lenalidomide, and tumor necrosis factor-α coupled with NGR, is warranted. Combining a high CNS-IPI score and ABC/classified COO were reported to identify a patient subgroup at high risk for developing CNS relapse. Of note, in the present trial, 90% of patients in the CNS-IPI high-risk group were ABC/unclassified DLBCL. However, in four patients with CNS relapse, one patient had primary testicular lymphoma, which should be treated with a specific treatment strategy including local radiotherapy. Moreover, 2 of the 4 patients with CNS relapse had high-grade B-cell lymphoma, NOS with MYC translocation, which is known to result in a relatively high incidence of CNS relapse. These results suggest that CD5+ DLBCL diagnosed according to the 2008 WHO criteria was a heterogeneous lymphoma and that DA-EPOCH-R/HD-MTX might be beneficial for patients with CD5+ DLBCL in the WHO 2017 era.

As expected, the incidence of grade 3 peripheral motor neuropathy, peripheral sensory neuropathy and cardiac events was low (4%, 4%, and 0%, respectively) and was comparable to that in previous studies including DA-EPOCH-R. Two-thirds (66%) of the patients in this study experienced FN, and the incidence was higher than

### Table 3. Hematologic and non-hematologic toxicities.

| Event                        | Grade 1-2 | Grade 3 | Grade 4 | Grade 5 |
|------------------------------|-----------|---------|---------|---------|
| **Hematologic adverse event** |           |         |         |         |
| Neutropenia                  | 0         | 1 (2%)  | 46 (98%)| 0       |
| Leukopenia                   | 1 (2%)    | 0       | 46 (98%)| 0       |
| Thrombocytopenia             | 13 (28%)  | 22 (47%)| 12 (26%)| 0       |
| Anemia                       | 11 (23%)  | 26 (55%)| 10 (21%)| 0       |
| Febrile neutropenia          | –         | 31 (60%)|         | 0       |
| **Non-hematologic adverse event** |         |         |         |         |
| Blood bilirubin increased    | 9 (19%)   | 2 (4%)  | 0       | 0       |
| AST increased                | 36 (77%)  | 5 (11%) | 0       | 0       |
| ALT increased                | 30 (64%)  | 13 (28%)| 0       | 0       |
| Hyperglycemia                | 40 (85%)  | 1 (2%)  | 0       | 0       |
| Hypotension                  | 36 (77%)  | 7 (15%) | 0       | 0       |
| Hyperkalemia                 | 20 (43%)  | 0       | 1 (2%)  | 0       |
| Hypokalemia                  | 38 (81%)  | 8 (17%) | 0       | 0       |
| Hypocalcaemia                | 44 (94%)  | 1 (2%)  | 1 (2%)  | 0       |
| Cardiac disorders            | –         | 0       | 0       | 0       |
| Constipation                 | 31 (66%)  | 3 (6%)  | 0       | 0       |
| Ileus                        | 1 (2%)    | 2 (4%)  | 0       | 0       |
| Nausea                       | 33 (70%)  | 1 (2%)  | 0       | 0       |
| Vomiting                     | 9 (19%)   | 1 (2%)  | 0       | 0       |
| Infection                    | –         | 4 (9%)  | 0       | 0       |
| Allergic reaction            | 11 (23%)  | 0       | 0       | 0       |
| Tumor lysis syndrome         | 0         | 3 (6%)  | 1 (2%)  | 0       |
| Peripheral motor neuropathy  | 11 (23%)  | 2 (4%)  | 0       | 0       |
| Peripheral sensory neuropathy| 29 (62%)  | 2 (4%)  | 0       | 0       |
| Pneumonitis                  | 2 (4%)    | 1 (2%)  | 0       | 0       |
| Others                       | –         | 10 (21%)| 0       | 0       |

AST: aspartate aminotransferase; ALT: alanine aminotransferase. *Observed in 23% of all cycles of DA-EPOCH-R (Online Supplementary Table S3). One patient experienced tumor lysis syndrome with hyperkalemia after the first administration of rituximab. Catechol related infection (n=1), cellulitis (n=1), infective endocarditis (n=1), and urinary tract infection (n=1), oral mucositis (n=3), hypertension (n=2), pulmonary embolism (n=2), deep vein thrombosis (n=1), Palmar Plantar erythrodysesthesia syndrome (n=1), and anorexia (n=1).
that in previous reports (36-37%). However, the incidence of FN per cycle of DA-EPOCH in our study was 23%, which was comparable to that in previous reports for DA-EPOCH-R (19%). The long period (7 months) of this protocol treatment may have resulted in the high proportion of patients who experienced FN. All patients with FN promptly recovered after initial antibiotic therapy and had no serious events. Hence, the toxicity could be considered manageable.

Second, 96% of the patients had good PS (< 2). Third, the portion of patients who experienced FN. All patients with CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(8):1551-1558.

We would like to thank all of the patients, hematolo-oncologists, and pathologists at the participating institutes for invaluable contributions to this multicenter study. Acknowledgments

Funding

This study was supported by grants-in-aid from the Japan Agency for Medical Research and Development, AMED (the Practical Research for Innovative Cancer Control; JP15ak0106157, JP16ak0106157, JP17ak0106157, JP18ek010643), the Ministry of Labour, Health, and Welfare of Japan (20140342A), the director of Meiji University Hospital (2012, 2013), and the National Cancer Center Research and Development Fund (26-A-4, 29-A-3).

References

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press, 2008.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC Press, 2017.
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1987-1997.
4. Lenz C, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
5. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815-821.
6. Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195-1202.
7. Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2006;19(11):1921-1926.
8. Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 357 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601-1607.
9. Xu-Monetette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615-5633.
10. Alinani L, Grau A, Quinon C, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):595-599.
11. Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28(1):27-35.
12. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood. 2009;113(16):3775-3780.
13. Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117(26):7070-7078.
14. Chuang WY, Chang H, Shih LY, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Arch. 2015;467(5):571-582.
15. Suguro M, Tagawa H, Kagami Y, et al. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature. Cancer Sci. 2006;97(9):686-697.
16. Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102(2):188-194.
17. Wilson WH, Dunleavy K, Patuluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-765.
18. Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-2418.
19. Miyazaki K, Yamaguchi M, Umino A, et al. DA-EPOCH-R Combined With High-dose Methotrexate For Newly Diagnosed CD5-positive Diffuse Large B-cell Lymphoma. Hematol Oncol. 2013;31:227.
20. Feugier P, Van Hoof A, Sebba C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117-4126.
21. Wilson WH, Grossbard ML, Patuluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large-B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
22. Pantek J, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
23. Scott DW, Wright GW, Williams PA, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;125(6):1214-1217.
24. Schmitz N, Zeynalova S, Nicke1en M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large-B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150-3156.
25. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
26. Bastard P, Wilson WH, Jung SH, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large-B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1793-1799.
27. Thakral B, Meideros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415-421.
30. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896-3902.

31. Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-1052.

32. Gleeson M, Counsell N, Cunningham D, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511-2516.

33. Grommes C, Pastore A, Falakas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7(9):1018-1029.

34. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133(5):436-445.

35. Ghesquiere H, Chevrier M, Laadham M, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intracranial lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol. 2019;30(4):621-628.

36. Ferreri AJM, Calimeri T, Conte GM, et al. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-alpha in primary CNS lymphoma. Blood. 2019;134(8):252-262.

37. Klanova M, Sehn LH, Bence-Bruckler I, et al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919-926.

38. Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766-2772.

39. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.

40. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multi-centre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e617.